FORMULATION ARTICLES
-
Oligos, mRNA, Or Gene Editing: Where Should You Bet?
Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.
-
A Smarter Switch: Reprogramming CIP Systems With Nanobodies Unlocks New Control Over Cell Signaling
Engineered nanobodies reprogram CIP systems, enabling precise, reversible control of protein interactions, signaling pathways, and gene expression without redesigning core chemistry.
-
Can Making mRNA More "Rigid" Unlock The Next Leap In RNA Medicines?
Can stabilizing mRNA structure unlock better performance? New strategies aim to “rigidify” mRNA, improving translation, stability, and manufacturability while reducing variability across conditions.
-
Rethinking The Oligonucleotide Backbone: A New Approach To RNA Therapeutic Design
Backbone engineering reframes RNA design, enabling programmable charge, uptake, and delivery — transforming oligonucleotides from fixed structures into tunable, multifunctional therapeutic systems.
-
AI Foundation Models For RNA Biology
AI foundation models are transforming RNA biology by learning sequence–structure–function relationships, enabling accurate predictions, scalable discovery, and deeper insight into RNA regulation and design.
-
Nanosystems And Rare Diseases: Opportunities And Limitations
Nanosystems offer unique capabilities, enabling researchers to design precise, versatile delivery systems that address key challenges in rare diseases.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.
-
As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality.
-
Virus filtration is robust across a wide range of process parameters, including high protein concentration and flow decay. Discover how retention relies on size exclusion to simplify risk assessment.
-
Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry.
-
Explore the automated production of protein microparticles using an innovative method that offers a standardized and scalable solution for co-precipitation in biopolymer particle fabrication.
-
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.